Company Overview and News

to your dashboard

Headline News

Intel, Microsoft Dominate DJIA Friday

5h 247wallst
December 15, 2017: Markets opened higher again Friday and continue to put up gains throughout the day. All three major equities indexes posted new intra-day highs as all sectors traded in the green, led by financials and consumer staples. WTI crude oil for January delivery settled at $57.30 a barrel, up 0.5% for the day, but down 0.1% for the week. February gold added just 40 cents on the day to settle at $1,257. (65-0)

Merck's Keytruda Misses Primary End Point for Gastric Cancer

7h zacks
Merck (MRK - Free Report) announced disappointing results from a pivotal phase III KEYNOTE-061 study, evaluating its anti-PD-1 therapy, Keytruda (pembrolizumab), as a second-line treatment for patients with advanced gastric or gastroesophageal junction (“GEJ”) adenocarcinoma. (75-0)

Pfizer's Arthritis Drug Gets FDA Nod for Label Expansion

7h zacks
Pfizer Inc. (PFE - Free Report) announced that the FDA has approved a label expansion for its janus kinase (JAK) inhibitor, Xeljanz (tofacitinib), for two doses — 5 mg twice daily and 11 mg once-daily extended-release (XR) formulation. (156-0)

Cancer Space Update: Roche, Pfizer & Regeneron Make Data Presentations

7h zacks
The week was marked by a flurry of data presentations by several companies at the 59th annual meeting of the American Society of Hematology held between Dec 9 and Dec 12. The presentations also included new/updated data from ongoing clinical studies on different cancer candidates. (74-0)

pSivida's Encouraging Knee Osteoarthritis Data

8h seekingalpha
pSivida's newly released data, although a small sample size, looks to be a unique and effective treatment for knee osteoarthritis. (79-0)

Pfizer Headed for New High After FDA Nod for Joint Disease Treatment

14h 247wallst
Shares of Pfizer Inc. (NYSE: PFE) rose about 1.3% in afterhours trading Thursday after the company announced that the U.S. Food and Drug Administration (FDA) had approved Xeljanz (tofacitinib) for the treatment of adult patients with active psoriatic arthritis. (20-0)

Inside the Mad Dash to Bring You Cheap, Generic Viagra

15h bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (284-0)

Pfizer: Strong Cash Flow, Improving Pipeline, And A Dividend Hike Coming Up

17h seekingalpha
Revenue has declined so far in 2017, but acquisitions and a strong pipeline should restore future revenue growth. (6-0)

Test Portfolio Results And Introducing A New Quality Portfolio

2017-12-14 seekingalpha
The one portfolio had the highest EPS growth expectations for the next five year (portfolio A), the other portfolio had the lowest EPS growth expectations (portfolio B). (368-1)

Pfizer's Second Biosimilar of Remicade Receives FDA Approval

2017-12-14 zacks
Pfizer Inc. (PFE - Free Report) announced that the FDA has approved Ixifi its second biosimilar version of Johnson & Johnson's (JNJ - Free Report) blockbuster rheumatoid arthritis (“RA”) drug, Remicade (infliximab). Notably, Ixifi is a chimeric human-murine monoclonal antibody against tumor necrosis factor. (88-0)

More Positives For Roche, The Core Biotech For The Long Run

2017-12-14 seekingalpha
Biotech and diagnostics company Roche provided several pieces of new or more detailed data over the past month, yet the stock just sits there. (150-0)

Wired News – Myriad Genetics' EMBRACA Trials Show Positive Results for BRACAnalysis CDx(R) Test on Patients with Metastatic Breast Cancer Responding to Pfizer's Talazoparib

2017-12-14 accesswire
LONDON, UK / ACCESSWIRE / December 14, 2017 / Active-Investors issued a free report on Myriad Genetics, Inc. (NASDAQ: MYGN) ("Myriad"), which is readily accessible upon registration at as the Company's latest news hit the wire. On December 12, 2017, the Company announced that the data from its EMBRACA clinical trials indicate that its BRACAnalysis CDx® test is able to positively identify patients with metastatic breast cancer (MBC) who responded to Pfizer Inc. (44-0)

Your Daily Pharma Scoop: Right Time To Buy Regeneron, Eli Lilly Gives Guidance, Bluebird Announces Offering

2017-12-14 seekingalpha
Today we will discuss an article on Regeneron (REGN) by Ed Wijarankula, titled, “Buy Celgene And Regeneron On The Dips As Insiders Are Buying.” We recently covered Celgene in our daily scoop so this article will only focus on Regeneron. (135-0)

Spark Therapeutics Foresees Its Recovery

2017-12-14 seekingalpha
Spark stock sank 35% on Monday and continues to sink due to the preliminary hemophilia A therapy data. (57-0)

Can Adamis Bleed Mylan Dry?

2017-12-13 seekingalpha
On Dec. 12th, I had a lengthy phone conversation with Mark Flather, Adamis’ head of investor relations. (40-1)

CUSIP: 717081103